For example, in 2019, and in line with the latter recommendation, the BRCA1 c.131G mutation was considered a founder mutation in the Lebanese population as it was detected among 23% of individuals diagnosed with BRCA mutation, and in Turkey, the positivity prevalence of BRCA1/2 mutation was 19% in high-risk BC patients (31, 33). The gene discussed is BRCA1; the disease is breast cancer.